X

Drug Profile

Research programme: regulatory T-cell therapies - Regeneron Pharmaceuticals/Sonoma Biotherapeutics

Latest Information Update: 25 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regeneron Pharmaceuticals; Sonoma Biotherapeutics
Class Anti-inflammatories; Gene therapies; Regulatory T lymphocyte cell therapies
Mechanism of Action Regulatory T-lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Crohn's disease; Ulcerative colitis

Most Recent Events

28 Mar 2023 Sonoma Biotherapeutics and Regeneron Pharmaceuticals enters into a R&D agreement for Regulatory T-cell therapy for Autoimmune Diseases
28 Mar 2023 Early research in Crohn's disease in USA (Parenteral)
28 Mar 2023 Early research in Ulcerative colitis in USA (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com